Milca Asanghanwa1, Frans K Gorus2, Ilse Weets2, Bart V der Auwera1, Folefac Aminkeng3, Eric Mbunwe1, Patrick Goubert4, Katrijn Verhaeghen4, Eugene Sobngwi5, Janet M Wenzlau6, John C Hutton6, Daniel G Pipeleers1, Bart Keymeulen2, Jean-Claude N Mbanya5, Chris van Schravendijk7. 1. Diabetes Research Center, Brussels Free University - VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium. 2. Diabetes Research Center, Brussels Free University - VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium; Department of Clinical Chemistry and Radio-immunology, University Hospital Brussels Free University - UZ Brussel, Brussels, Belgium. 3. The Canadian Pharmacogenomics Network for Drug Safety, University of British Columbia, Canada. 4. Department of Clinical Chemistry and Radio-immunology, University Hospital Brussels Free University - UZ Brussel, Brussels, Belgium. 5. Faculty of Medicine and Biomedical Sciences, Department of Medicine and Specialties, Laboratory for Molecular and Metabolic Medicine, The Biotechnology Centre, University of Yaoundé 1, Yaoundé, Cameroon. 6. Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver, Aurora, CO, United States. 7. Diabetes Research Center, Brussels Free University - VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium. Electronic address: chrisvs@vub.ac.be.
Abstract
AIMS: We investigated the prevalence of diabetes autoantibodies (Abs) in Cameroonian patients and controls, assessed their contribution in disease classification and compared results with data from Belgium. METHODS: Abs against GAD (GADA), IA-2 (IA-2A) and zinc transporter 8 (ZnT8A) were assessed in 302 recently diagnosed Cameroonian patients with diabetes and 184 control subjects without diabetes aged below 40 years. RESULTS: Only 27 (9%) Cameroonian patients were younger than 15 years. Overall, 29% of patients presented at least one diabetes-associated antibody vs 9% in healthy controls (24% vs 7% for GADA (p<0.001), 10% vs 3% for IA-2A (p<0.006), 4% vs 2% for ZnT8A). Ab(+) patients had lower C-peptide levels (p<0.001), were more often insulin-treated (p<0.002) and were as frequently diagnosed with type 1 diabetes as Ab(-) patients. Only 43% of Ab(+) patients aged 15-39 years were clinically classified as having type 1 diabetes in Cameroon vs 96% in Belgium (p<0.001). Not one Ab(+) Cameroonian patient carried HLA-DQ2/DQ8 genotype vs 23% of Belgian Ab(+) patients (p<0.001). Younger age at diagnosis and antibody positivity were independent predictors of insulin therapy. Ab(+) Cameroonian patients were older (p<0.001), had higher BMI (p<0.001) and lower Ab titers than Belgian Ab(+) patients. In ketonuric patients, prevalence of autoantibodies was similar as in non-ketonuric patients. CONCLUSIONS: In Cameroonian patients with diabetes aged under 40 years, antibody-positivity is not clearly related to disease phenotype, but may help predict the need for insulin treatment.
AIMS: We investigated the prevalence of diabetes autoantibodies (Abs) in Cameroonian patients and controls, assessed their contribution in disease classification and compared results with data from Belgium. METHODS: Abs against GAD (GADA), IA-2 (IA-2A) and zinc transporter 8 (ZnT8A) were assessed in 302 recently diagnosed Cameroonian patients with diabetes and 184 control subjects without diabetes aged below 40 years. RESULTS: Only 27 (9%) Cameroonian patients were younger than 15 years. Overall, 29% of patients presented at least one diabetes-associated antibody vs 9% in healthy controls (24% vs 7% for GADA (p<0.001), 10% vs 3% for IA-2A (p<0.006), 4% vs 2% for ZnT8A). Ab(+) patients had lower C-peptide levels (p<0.001), were more often insulin-treated (p<0.002) and were as frequently diagnosed with type 1 diabetes as Ab(-) patients. Only 43% of Ab(+) patients aged 15-39 years were clinically classified as having type 1 diabetes in Cameroon vs 96% in Belgium (p<0.001). Not one Ab(+) Cameroonian patient carried HLA-DQ2/DQ8 genotype vs 23% of Belgian Ab(+) patients (p<0.001). Younger age at diagnosis and antibody positivity were independent predictors of insulin therapy. Ab(+) Cameroonian patients were older (p<0.001), had higher BMI (p<0.001) and lower Ab titers than Belgian Ab(+) patients. In ketonuric patients, prevalence of autoantibodies was similar as in non-ketonuric patients. CONCLUSIONS: In Cameroonian patients with diabetes aged under 40 years, antibody-positivity is not clearly related to disease phenotype, but may help predict the need for insulin treatment.
Authors: I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus Journal: Diabetologia Date: 2005-10-07 Impact factor: 10.122
Authors: F K Gorus; P Goubert; C Semakula; C L Vandewalle; J De Schepper; A Scheen; M R Christie; D G Pipeleers Journal: Diabetologia Date: 1997-01 Impact factor: 10.122
Authors: Sanjeet G Patel; Jean W Hsu; Farook Jahoor; Ivonne Coraza; James R Bain; Robert D Stevens; Dinakar Iyer; Ramaswami Nalini; Kerem Ozer; Christiane S Hampe; Christopher B Newgard; Ashok Balasubramanyam Journal: Diabetes Date: 2012-11-16 Impact factor: 9.461